AnPac Bio Granted a New US patent on Novel Medical Gadget for Multi-Most cancers Detection

Tom Smith

SAN JOSE, Calif., Feb. 01, 2021 (Globe NEWSWIRE) — AnPac Bio-Professional medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with functions in China and the United States targeted on early cancer screening and detection, introduced nowadays that a new U.S. patent titled “Apparatus […]

SAN JOSE, Calif., Feb. 01, 2021 (Globe NEWSWIRE) — AnPac Bio-Professional medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with functions in China and the United States targeted on early cancer screening and detection, introduced nowadays that a new U.S. patent titled “Apparatus for Detecting Tumor Cells” (patent amount 10,895,573) was granted to the Firm by the United States Patent and Trademark Office on January 19, 2021, AnPac Bio’s 20th patent granted in the U.S. The patent is made up of 38 promises and handles a array of novel characteristics for multi-most cancers detection, which has come to be increasingly vital, and addresses the cancer detection apparatus, components of the equipment, reagents, detection mechanisms, and a wide vary of detection parameters, together with bio-physical qualities.

AnPac Bio has been focusing on innovation and IP make-up since its inception, with over 200 patent apps submitted together with around 100 patents issued in almost 20 nations around the world and areas. In unique, AnPac Bio has devoted important efforts and sources in mental house (IP) security in the U.S., with 20 U.S. patents issued and additional U.S. patent applications pending.   

Dr. Chris Yu, AnPac Bio’s CEO, commented: “We are pretty happy of owning yet another U.S. patent issued in the essential house of multi-most cancers detection, which is a important marketplace and is expected to keep on to grow. Some of the novel features and know-how elements in the issued patent are staying implemented into our new cancer screening products and solutions which will have increased detection efficiency and are predicted to have more competitive positive aspects more than traditional most cancers screening and detection technologies. Additional, the 20th U.S. patent issued to AnPac Bio strengthens our patent portfolio and IP protection of our novel engineering and goods.”

About AnPac Bio

AnPac Bio is a biotechnology business focused on early most cancers screening and detection, with 128 issued patents as of June 30, 2020. With two licensed scientific laboratories in China, as nicely as just one CLIA and CAP accredited medical laboratory and one CLIA registered clinical laboratory in the U.S., AnPac Bio performs a suite of most cancers screening and detection checks, together with CDA (Most cancers Differentiation Evaluation), bio-chemical, immunological, and genomics checks. According to Frost & Sullivan, AnPac Bio ranked third around the world amid organizations featuring future-technology early most cancers screening and detection technologies in phrases of the amount of scientific samples for cancer screening and detection, dependent on around 41,700 medical samples as of Could 2020. AnPac Bio’s CDA engineering platform has been demonstrated in retrospective validation studies to be capable to detect the chance of above 20 unique most cancers styles with substantial sensitivity and specificity.

For additional information and facts, make sure you check out:

For investor and media inquiries, please speak to:


Phil Circumstance, Promoting and Trader Relations
Telephone: +1-267-810-6776 (U.S.)
E-mail:  [email protected]

Investor Relations:

Ascent Trader Relations LLC
Tina Xiao, President
Cellular phone: +1-917-609-0333 (U.S.)
E-mail:  [email protected]    

Protected Harbor Statement

This announcement incorporates ahead-on the lookout statements inside of the which means of Area 27A of the Securities Act of 1933 and Segment 21E of the Securities Exchange Act of 1934, such as the statements from the Company’s management. These forward-wanting statements are made underneath the “safe harbor” provisions of the Personal Securities Litigation Reform Act of 1995 and are relating to the Company’s upcoming monetary and running overall performance. The Firm has tried to identify forward-seeking statements by terminologies which includes “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other text that convey uncertainty of future activities or results to detect these forward-searching statements. These statements are centered on existing expectations, assumptions and uncertainties involving judgments about, between other points, long run financial, competitive and market conditions and long run company selections, all of which are difficult or unattainable to predict precisely and lots of of which are further than the Company’s handle. These statements also contain recognised and unidentified dangers, uncertainties and other factors that may cause the Company’s precise effects to be materially unique from individuals expressed or implied by any ahead-on the lookout assertion. Acknowledged and mysterious hazards, uncertainties and other factors incorporate, but are not limited to, the implementation of our business enterprise product and growth techniques developments and competition in the cancer screening and detection market place our anticipations relating to need for and industry acceptance of our most cancers screening and detection exams and our ability to grow our client base our capacity to obtain and sustain intellectual assets protections for our CDA technology and our ongoing analysis and enhancement to maintain rate with engineering developments our ability to get hold of and preserve regulatory approvals from the NMPA, the Food and drug administration and the suitable U.S. states and have our laboratories accredited or accredited by authorities such as the CLIA our future business enterprise improvement, fiscal issue and benefits of operations and our potential to get funding value-proficiently likely improvements of govt laws standard financial and enterprise disorders in China and elsewhere our means to employ the service of and preserve critical personnel our relationship with our big business enterprise companions and consumers and the length of the coronavirus outbreaks and their potential adverse impression on the financial ailments and economic markets and our small business and financial performance, these as ensuing from minimized professional things to do because of to quarantines and travel restrictions instituted by China, the U.S. and a lot of other nations all-around the earth to have the spread of the virus. In addition, all ahead-searching statements are issue to the “Risk Factors” thorough from time to time in the Company’s most modern Annual Report on Sort 20-F and other filings with the U.S. Securities and Trade Commission. Mainly because of these and other hazards, uncertainties and assumptions, undue reliance should not be put on these forward-wanting statements. In addition, these statements speak only as of the day of this push release and, apart from as may possibly be expected by law, the Business undertakes no obligation to revise or update publicly any ahead-wanting statements for any purpose.

Next Post

Artificial Intelligence in Drugs Market Research Report by Software, by Stop User - Global Forecast to 2025 - Cumulative Impression of COVID-19

New York, Jan. 29, 2021 (Globe NEWSWIRE) — announces the launch of the report “Artificial Intelligence in Drugs Marketplace Research Report by Software, by Finish Person – Worldwide Forecast to 2025 – Cumulative Impact of COVID-19” – Marketplace Figures:The report delivers current market sizing and forecast across 5 […]

Subscribe US Now